I surely hope that JT didn't just start considering BO on March 30, 2020. He would be an idiot if he did this. I don't think he is. But I do think he grossly over-estimated the capabilities of a small-medium sized pharma and under-estimated the risks associated with the fact that EPA is a natural molecule with a long history as a supplement and being heavily studied. I only dipped my toe in the DS market for a year, and I felt the risks. He has been in the business for ten years. He should have known this very well, better than any shareholders. So it's very frustrating to see him being so cavalier to GIA even in the US. That frustration is aggravated by his communication style.
He made the CEO of Omthera like a genius. Omethera was sold early for $12.7/sh or 88% premium with a CVR of $4.7/sh. I never believed in EPANOVA and used to laugh AZN for being scientifically incompetent. But guess what, Omthera did well for its shareholders - good exit and early exit for a crappy product. I guess this is called business acumen. I am trying very hard to find this in JT.
FWIW, I heard anecdotal stories on BO offers last year, but sounds they were around marcap. Hence nothing was materialized as the company was on the hype of FDA approval.
I will stop posting my frustration. Will join all to take a blank faith in him making a sensible decision.
News 
Market Data 
Discover 
AI
